Great Basin Scientific initiated clinical trials for the Stool Bacterial Pathogens Panel in April 2016. Great Basin Scientific currently has four commercially available tests, the Staph ID/R Blood Culture Panel, Shiga Toxin Direct Test, tests for Group B Streptococcus (GBS), and toxigenic Clostridium difficile (C. diff). The Company also has four tests in development phase; Nasal S. aureus Pre-surgical Screen, Candida Blood Infections Panel, CT/NG Test, and the Bordetella Direct test.About Great Basin ScientificGreat Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company's website at www.gbscience.com. Forward-Looking Statements This press release includes forward-looking statements regarding the Company's continuing business efforts related to its products, including but not limited to statements regarding the Company's intent to seek 510(k) clearance from the FDA for the Stool Bacterial Pathogens Panel and CE marking, the potential future marketing of the the Stool Bacterial Pathogens Panel if FDA clearance is obtained, the potential benefits of the the Stool Bacterial Pathogens Panel for the Company's potential customers, planned tests to be brought to clinical trial in 2016, expansion of the Company's menu, the Company's development goals and other similar statements. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and Quarterly Report on From 10-Q for the quarter ended June 30, 2016. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.
Media Contact:Nirav SuchakICR646.firstname.lastname@example.orgInvestor Relations Contact:Betsy HartmanGreat Basin Scientific385.email@example.com